267 related articles for article (PubMed ID: 16799620)
1. Dysregulation of growth factor signaling in human hepatocellular carcinoma.
Breuhahn K; Longerich T; Schirmacher P
Oncogene; 2006 Jun; 25(27):3787-800. PubMed ID: 16799620
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of apoptosis in hepatocellular carcinoma.
Thorgeirsson SS; Teramoto T; Factor VM
Semin Liver Dis; 1998; 18(2):115-22. PubMed ID: 9606809
[TBL] [Abstract][Full Text] [Related]
3. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.
Cantarini MC; de la Monte SM; Pang M; Tong M; D'Errico A; Trevisani F; Wands JR
Hepatology; 2006 Aug; 44(2):446-57. PubMed ID: 16871543
[TBL] [Abstract][Full Text] [Related]
4. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II.
Lund P; Schubert D; Niketeghad F; Schirmacher P
Cancer Lett; 2004 Mar; 206(1):85-96. PubMed ID: 15019164
[TBL] [Abstract][Full Text] [Related]
5. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
6. [Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].
Nussbaum T; Samarin J; Schirmacher P; Breuhahn K
Verh Dtsch Ges Pathol; 2007; 91():278-85. PubMed ID: 18314625
[TBL] [Abstract][Full Text] [Related]
7. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
[TBL] [Abstract][Full Text] [Related]
8. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.
Aishima S; Basaki Y; Oda Y; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Hosoi F; Maruyama Y; Fotovati A; Oie S; Ono M; Ueno T; Sata M; Yano H; Kojiro M; Kuwano M; Tsuneyoshi M
Cancer Sci; 2006 Nov; 97(11):1182-90. PubMed ID: 16965600
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma.
Liu X; Jiang W; Aucejo F; Kim R; Miller C; Byrne M; Lopez R; Yerian L
Hum Pathol; 2011 Jun; 42(6):882-91. PubMed ID: 21292299
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
11. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 in hepatocellular carcinoma.
Wu T
Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
[TBL] [Abstract][Full Text] [Related]
13. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis.
Martínez-Iglesias O; Garcia-Silva S; Tenbaum SP; Regadera J; Larcher F; Paramio JM; Vennström B; Aranda A
Cancer Res; 2009 Jan; 69(2):501-9. PubMed ID: 19147563
[TBL] [Abstract][Full Text] [Related]
14. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IGF receptor signaling and hepatoma cell growth by an antibody to ligand oligopeptide of receptor.
Kong J; Diao Z; Deng X
Growth Factors; 2008 Feb; 26(1):35-43. PubMed ID: 18365877
[TBL] [Abstract][Full Text] [Related]
16. Induction of glutathione transferase in insulin-like growth factor type I receptor-overexpressed hepatoma cells.
Lee JY; Han CY; Yang JW; Smith C; Kim SK; Lee EY; Kim SG; Kang KW
Mol Pharmacol; 2007 Oct; 72(4):1082-93. PubMed ID: 17615245
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of PI-3' kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis.
Alexia C; Bras M; Fallot G; Vadrot N; Daniel F; Lasfer M; Tamouza H; Groyer A
Ann N Y Acad Sci; 2006 Dec; 1090():1-17. PubMed ID: 17384242
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.
Himpe E; Kooijman R
Biofactors; 2009; 35(1):76-81. PubMed ID: 19319849
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
